Case Western Reserve University works with NYU and pharmaceutical companies Bristol Myers Squibb, AstraZeneca to validate imaging-based solutions for predicting response to therapy for lung cancer patients

For artificial intelligence (AI) tools being developed at Case Western Reserve University to have impact in the fight against cancer, they’re going to have to be validated in rigorous human clinical trials.

That validation may be a step closer following two recent agreements among bioengineering pioneer Anant Madabhushi, a longtime collaborator at New York University, and select large pharmaceutical companies:

In April, Madabhushi entered into a contract with AstraZeneca (LSE/STO/NYSE: AZN), a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in three therapy areas—oncology; cardiovascular, renal and metabolism; and respiratory and immunology.

Earlier this year, Madabhushi inked a similar deal with United States-based Bristol-Myers Squibb Company (NYSE: BMY), a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases.

“This is an important step in not only validating our research, but in further advancing efforts to get the right treatment to the patients who will benefit the most,” said Madabhushi, the F. Alex Nason Professor II of Biomedical Engineering at Case Western Reserve and director of the Center for Computational Imaging and Personalized Diagnostics (CCIPD). “We have shown that our AI, our computational-imaging tools, can have the potential to predict an individual cancer patient’s response to immunotherapy.”

Click here to read the complete story.

Story excerpt provided by The Daily.

Written by Mike Scott.

Originally published Sept. 10, 2020.

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.

%d bloggers like this: